We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+0.56%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$134M
AUM Growth
–
Cap. Flow
+$136M
Cap. Flow
% of AUM
101.13%
Top 10 Holdings %
Top 10 Hldgs %
64.42%
Holding
29
New
28
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
+$17.6M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$12.5M |
| 3 |
MacroGenics
MGNX
|
+$11.3M |
| 4 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$8.08M |
| 5 |
Sabra Healthcare REIT
SBRA
|
+$8M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 79.86% |
| 2 | Real Estate | 5.62% |
| 3 | Consumer Discretionary | 3.73% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CFMS
26
DELISTED
Conformis, Inc. Common Stock
CFMS
| $952K | 0.71% |
+16,000
| New | +$1.28M |
|
|
NVLN
27
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $925K | 0.69% |
+296,488
| New | +$1.43M |
|
28
Acadia Healthcare
ACHC
$3.02B
| $878K | 0.65% |
+26,916
| New | +$933K |
|
|
ADMS
29
DELISTED
Adamas Pharmaceuticals
ADMS
| $407K | 0.3% |
+12,000
| New | +$335K |
|
Similar funds
PL
BFC
ACM
FFWA
SAM
CBB
AIG
IA